Low-Level Subchronic Arsenic Exposure from Prenatal Developmental Stages to Adult Life Results in an Impaired Glucose Homeostasis

 

 Buy Article Permissions and Reprints

Abstract

We evaluated how low-level (3 ppm) subchronic inorganic arsenic (iAs) exposure from prenatal developmental stages until adult life affects glucose homeostasis. Biochemical parameters of glucose and lipid metabolism, pancreatic insulin and glycosylated haemoglobin were determined in 4-month-old female offspring of adult Wistar rats. Pancreatic histology was also performed. Statistical comparisons between control and iAs-treated groups were performed by unpaired two-tailed Student’s t-test. Statistical significance was set at p<0.05. We found that iAs treatment resulted in an impaired glucose tolerance test, suggestive of impaired glucose metabolism. This group was found to have hyperglycaemia and high levels of HOMA-IR, glycosylated haemoglobin, cholesterol and pancreatic insulin compared to control rats. However, plasma insulin, triglycerides and high-density lipoprotein cholesterol were not different from control rats. Moreover, β-cell damage found in iAs-treated rats consisted of cells with a nucleus with dense chromatin and predominance of eosinophilic cytoplasm, as well as changes in the pancreatic vasculature. The current study provided evidence that subchronic iAs exposure at 3 ppm from prenatal developmental stages to adult life resulted in damage to pancreatic β cells, affected insulin secretion and demonstrated altered glucose homeostasis, thus supporting a causal association between iAs exposure and diabetes.

• References

• 1 Aratan-Spire S, Wolf B, Portha B et al. Streptozotocin treatment at birth induces a parallel depletion of thyrotropin-releasing hormone and insulin in the rat pancreas during development. Endocrinology 1984; 114: 2369-2373
  CrossrefPubMedGoogle Scholar
• 2 Bacová Z, Najvirtová M, Krizanová O et al. Effect of neonatal streptozotocin and thyrotropin-releasing hormone treatments on insulin secretion in adult rats. Gen Physiol Biophys 2005; 24: 181-197
  PubMedGoogle Scholar
• 3 Benicky J, Strbak V. Glucose stimulates and insulin inhibits release of pancreatic TRH in vitro. Eur J Endocrinol 2000; 142: 60-65
  CrossrefPubMedGoogle Scholar
• 4 Best HC, Haist RE, Ridout JE. Diet and the insulin content of the pancreas. J Physiol 1939; 97: 107-119
  PubMedGoogle Scholar
• 5 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
  CrossrefPubMedGoogle Scholar
• 6 Cobo JM, Castiñera M. Oxidative stress, mitochondrial respiration, and glycemic control: clues from chronic supplementation with Cr3+ or As3+ to male Wistar rats. Nutrition 1997; 13: 965-970
  CrossrefPubMedGoogle Scholar
• 7 Coronado-González JA, Del Razo LM, García-Vargas G et al. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res 2007; 104 (03) 383-389
  CrossrefPubMedGoogle Scholar
• 8 Dávila-Esqueda ME, Jiménez-Capdeville ME, Delgado JM et al. Effects of arsenic exposure during the pre- and postnatal development on the puberty of female offspring. Exp Toxicol Pathol 2010; [Epub ahead of print]. Article in press. http://dx.doi.org/10.1016/j.etp.2010.06.001
  PubMedGoogle Scholar
• 9 Díaz-Villaseñor A, Sánchez-Soto MC, Cebrián ME et al. Sodium arsenite impairs insulin secretion and transcription in pancreatic beta-cells. Toxicol Appl Pharmacol 2006; 214: 30-34
  CrossrefPubMedGoogle Scholar
• 10 Díaz-Villaseñor A, Burns AL, Salazar AM et al. Arsenite reduces insulin secretion in rat pancreatic beta-cells by decreasing the calcium-dependent calpain-10 proteolysis of SNAP-25. Toxicol Appl Pharmacol 2008; 231: 291-299
  CrossrefPubMedGoogle Scholar
• 11 Duntas LH, Papanastasiou L, Mantzou E et al. Inhibitory action of oral thyrotropin-releasing hormone on the glucoregulatory response of the oral glucose tolerance test. Thyroid 1998; 8: 929-933
  CrossrefPubMedGoogle Scholar
• 12 Fu J, Woods CG, Yehuda-Shnaidman E et al. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect 2010; 118: 864-870
  CrossrefPubMedGoogle Scholar
• 13 Lai MS, Hsueh YM, Chen CJ et al. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol 1994; 139: 484-492
  PubMedGoogle Scholar
• 14 Leduque P, Aratan-Spire S, Wolf B et al. Localization of thyrotropin-releasing hormone- and insulin-immunoreactivity in the pancreas of neonatal rats after injection of streptozotocin at birth. Cell Tissue Res 1987; 248: 89-94
  CrossrefPubMedGoogle Scholar
• 15 Matthews D, Hosker J, Rudenski A et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
  Google Scholar
• 16 Nadal A, Rovira JM, Laribi O et al. Rapid insulinotropic effect of 17 beta-estradiol via a plasma membrane receptor. FASEB J 1998; 12: 1341-1348
  PubMedGoogle Scholar
• 17 Nadal A, Alonso-Magdalena P, Soriano S et al. The role of oestrogens in the adaptation of islets to insulin resistance. J Physiol 2009; a 587: 5031-5037
  CrossrefPubMedGoogle Scholar
• 18 Nadal A, Alonso-Magdalena P, Soriano S et al. The pancreatic β-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol 2009; b 304: 63-68
  CrossrefPubMedGoogle Scholar
• 19 Pal S, Chatterjee AK. Protective effect of N-acetylcysteine against arsenic-induced depletion in vivo of carbohydrate. Drug Chem Toxicol 2004; b 27: 179-189
  PubMedGoogle Scholar
• 20 Nain S, Smits JE. Pathological, immunological and biochemical markers of subchronic arsenic toxicity in rats. Environ Toxicol 2010; [Epub ahead of print]. Article in press. DOI: 10.1002/tox.20635.
  PubMedGoogle Scholar
• 21 Tseng CH, Tseng CP, Chiou HY et al. Epidemiologic evidence of diabetogenic effect of arsenic. Toxicol Lett 2002; 133: 69-76
  CrossrefPubMedGoogle Scholar
• 22 Vahter M. Health effects of early life exposure to arsenic. Basic Clin Pharmacol Toxicol 2008; 102: 204-211
  CrossrefPubMedGoogle Scholar
• 23 Waalkes MP, Ward JM, Liu J et al. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol 2003; 186: 7-17
  CrossrefPubMedGoogle Scholar
• 24 Wang SL, Chiou JM, Chen CJ et al. Prevalence of non-insulin-dependent diabetes mellitus and related diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwain. Environ Health Perspect 2003; 111: 155-159
  PubMedGoogle Scholar
• 25 Xie Y, Liu J, Benbrahim-Tallaa L et al. Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology 2007; 236: 7-15
  CrossrefPubMedGoogle Scholar
• 26 Zarazúa S, Pérez Severiano F, Delgado JM et al. Decreased nitric oxide production in the rat brain after chronic arsenic exposure. Neurochem Res 2006; 31: 1069-1077
  CrossrefPubMedGoogle Scholar